The ESA Poster Awards are awarded to the highest scoring poster presentations including a Q&A with the judging committee at the poster sessions. Congratulations to the awardees for 2024: @asmeakin - Basic Science @MUmapathysivam - Clinical Tomasz Block - Clinical Case Report

ICYMI: #ENDO2024 #Diabetes News Conference | Drs. Mojca Jensterle Sever; @JenniferTichMD; @MUmapathysivam; and @carlosfermin_99 cover #socialvulnerability + #bloodsugarcontrol, #testosterone + #waistsize, #prediabetes, and #semaglutide + taste perception:

#ENDO2024 #diabetes news conference: @MUmapathysivam's research found testosterone appears to protect against type 2 #diabetes risk in men under 65. https://t.co/GQQqQ3axeL

So proud of our honours student, Caitlin Burt, winner of the NMT student award at the #ANZSNM24 ASM - @UniversitySA , @UniofAdelaide , @CRENutrition, @anzsnm1969, with co-supervisors @CristinaBlefari @MUmapathysivam

SGLT2i DKA was associated with milder presentation, twice the median time to resolution and half the amount of insulin administered on standard T1D-DKA dynamic insulin infusion protocol when compared to individuals with T1D-DKA of a similar age.

We describe 2 cases of severe ketoacidosis in individuals without #diabetes being treated with SGLT2i for heart failure @DiabetesCareADA

Rare but real-Euglycemic ketoacidosis in two HFrEF subjects without #diabetes with use of SGLT-2 inhibitors @DiabetesCareADA https://t.co/FFf14AQ0fE

Today we updated our lab 🥼 this is us wall with new papers & team photos! @StanfordPedEndo @yunkyeong_lee @tamadher_aa

New from @annagloyn Human carriers of hypomorphic #T2D risk alleles in the gene encoding peptidyl-glycine alpha-amidating monooxygenase (PAM) exhibit reduced glucose-lowering responses to Rxment with GLP-1R agonist, likely not related to #islet actions https://t.co/PFACb0sjCE

Thank you to all the researchers across 3 continents who have contributed to this work, the research participants and the funding bodies who have supported this work. Thank you and ttfn! @RDMOxford @rhodes_trust @The_MRC @wellcometrust @stanfordPedEndo /10

In a meta-analysis of 3 pharmacogenetics studies we show reduced efficacy GLP-1RA in carriers of PAM LoF alleles as measured by HbA1c 6 months after starting therapy #personalisedmedicine./9

In two independent models we demonstrated reduced GLP-1 action and in mice and in we demonstrated that this occurred due to reduced GLP-1 receptor expression and aberrant gastric emptying /8

In two independent models (mouse and human) and in both LoF alleles we demonstrated elevated postprandial GLP-1 levels /7

In two independent models (mouse and human) and in carriers of both LoF allele we demonstrated reduced PAM enzyme activity./6

We  demonstrate the impact of PAM LoF on serum PAM activity, the incretin system & treatment response in Pam knockout mice & human carriers of PAM LoF alleles./5

We teamed up with @ElisaAraldi & Mark Stoffel (who had a Pam knockout mouse) & @ezpearson & @angusgjones (who had generated pharmacogenetics datasets) & many others. /4

Back in 2014, #GWAS identified two PAM alleles (frequency: 5% and 1%) associated with altered risk for T2D, but it wasn't clear mechanistically how they could lead to diabetes. /3

Our work brings together mouse and human data, small bespoke physiology studies and large pharmacogenetics dataset to show that LoF alleles in PAM cause reduced PAM enzyme activity, GLP-1 resistance, more rapid gastric emptying and reduced response to GLP-1RA. /2

I'm excited & proud to share work from my DPhil @oxforduni & an amazing collaboration with @annagloyn, @markmccarthyoxf, @ElisaAraldi & Markus Stoffel. We show that variants in the #T2D risk gene PAM alter GLP-1 levels & response to GLP-1 receptor agonists https://t.co/mjTpdhwyrn

🚨Introducing an exciting story of 🐭and 👥, an extraordinary 🌎🌍🌏 collaboration featuring @annagloyn, @MUmapathysivam, Markus Stoffel @ETH_en We show that variants in the #T2D risk gene PAM affect GLP-1 levels & response to GLP-1 receptor agonists. https://t.co/pwq3IOXjFj